Johnson & Johnson (JNJ) EBIT (2009 - 2026)

Johnson & Johnson has disclosed EBIT across 18 years of filings, most recently posting $7.1 billion for Q2 2026.

• In Q2 2026, EBIT rose 7.43% year-over-year to $7.1 billion; the TTM figure through Jun 2026 stood at $26.0 billion (up 21.33% YoY), while the FY2025 annual figure was $25.4 billion, up 20.71% from the prior year.
• EBIT came in at $7.1 billion for Q2 2026 at Johnson & Johnson, up from $6.4 billion in the prior quarter.
• In the past five years, EBIT ranged from a high of $7.1 billion in Q2 2026 to a low of $3.6 billion in Q4 2024.
• Average EBIT over 5 years is $5.7 billion, with a median of $5.8 billion recorded in 2023.
• Year-over-year, EBIT plunged 38.1% in 2023 and jumped 53.01% in 2025.
• Over 5 years, EBIT stood at $5.3 billion in 2022, then retreated by 19.78% to $4.3 billion in 2023, then slipped by 15.34% to $3.6 billion in 2024, then jumped by 53.01% to $5.5 billion in 2025, then climbed by 29.65% to $7.1 billion in 2026.
• Per Business Quant data, the three most recent EBIT figures were $7.1 billion in Q2 2026, $6.4 billion in Q1 2026, and $5.5 billion in Q4 2025.